Pierfrancesco Tassone

List of Publications by Year
in descending order

286	15,498	13068	24915
papers	citations	68 h-index	109 g-index

289	289	289	18428
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 1688-1700.	5.1	451
2	Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2016, 17, 367-377.	5.1	444
3	Mir-34: A New Weapon Against Cancer?. Molecular Therapy - Nucleic Acids, 2014, 3, e195.	2.3	421
4	Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood, 2009, 114, 371-379.	0.6	364
5	BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. British Journal of Cancer, 2003, 88, 1285-1291.	2.9	342
6	Aggresome induction by proteasome inhibitor bortezomib and Î±-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood, 2006, 108, 3441-3449.	0.6	328
7	HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood, 2005, 105, 251-258.	0.6	291
8	MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches. Journal of Hematology and Oncology, 2018, 11, 63.	6.9	268
9	Dysfunctional T regulatory cells in multiple myeloma. Blood, 2006, 107, 301-304.	0.6	220
10	Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer. Human Mutation, 2001, 18, 163-164.	1.1	215
11	Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence. Clinical Cancer Research, 2012, 18, 6260-6270.	3.2	213
12	Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth. Clinical Cancer Research, 2013, 19, 2096-2106.	3.2	195
13	Regulatory (FoxP3+) T-cell Tumor Infiltration Is a Favorable Prognostic Factor in Advanced Colon Cancer Patients Undergoing Chemo or Chemoimmunotherapy. Journal of Immunotherapy, 2010, 33, 435-441.	1.2	190
14	Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. Leukemia, 2018, 32, 1948-1957.	3.3	179
15	Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT) Tj ETQq1 1 0.784314 rgBT /Overlock 8, 1132-1143.	5.2	169
16	In Vitro and in Vivo Activity of the Maytansinoid Immunoconjugate huN901-N2â€²-Deacetyl-N2â€²-(3-Mercapto-1-Oxopropyl)-Maytansine against CD56+ Multiple Myeloma Cells. Cancer Research, 2004, 64, 4629-4636.	0.4	157
17	miRâ€29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myelomaâ€related bone disease. Journal of Cellular Physiology, 2013, 228, 1506-1515.	2.0	156
18	Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation. Oncotarget, 2015, 6, 13772-13789.	0.8	147

#	Article	IF	Citations
19	Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood, 2007, 109, 1220-1227.	0.6	144
20	Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. British Journal of Cancer, 2003, 88, 1971-1978.	2.9	138
21	DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget, 2012, 3, 1246-1258.	0.8	138
22	miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death and Disease, 2012, 3, e436-e436.	2.7	137
23	Non-coding RNAs in cancer: platforms and strategies for investigating the genomic â€œdark matterâ€• Journal of Experimental and Clinical Cancer Research, 2020, 39, 117.	3.5	137
24	Integrin Î²7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. Blood, 2011, 117, 6202-6213.	0.6	134
25	Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia, 2000, 14, 841-844.	3.3	133
26	MLN120B, a Novel IÎºB Kinase Î² Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo. Clinical Cancer Research, 2006, 12, 5887-5894.	3.2	130
27	Bortezomib-induced â€œBRCAnessâ€•sensitizes multiple myeloma cells to PARP inhibitors. Blood, 2011, 118, 6368-6379.	0.6	125
28	In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma. Oncotarget, 2013, 4, 242-255.	0.8	125
29	Cytotoxic activity of the maytansinoid immunoconjugate B-B4â€“DM1 against CD138+ multiple myeloma cells. Blood, 2004, 104, 3688-3696.	0.6	122
30	Neutralizing B-Cellâ€“Activating Factor Antibody Improves Survival and Inhibits Osteoclastogenesis in a Severe Combined Immunodeficient Human Multiple Myeloma Model. Clinical Cancer Research, 2007, 13, 5903-5909.	3.2	122
31	Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma. Blood, 2012, 120, 5002-5013.	0.6	121
32	A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood, 2005, 106, 713-716.	0.6	115
33	miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies. Oncotarget, 2015, 6, 12837-12861.	0.8	112
34	Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma. Scientific Reports, 2015, 5, 17579.	1.6	110
35	Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood, 2007, 110, 1656-1663.	0.6	106
36	Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials. European Journal of Cancer, 2013, 49, 593-603.	1.3	106

#	Article	IF	Citations
37	Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo. Leukemia, 2015, 29, 2173-2183.	3.3	104
38	A High-Affinity Fully Human Antiâ€"IL-6 mAb, 1339, for the Treatment of Multiple Myeloma. Clinical Cancer Research, 2009, 15, 7144-7152.	3.2	103
39	In Vivo Activity of MiR-34a Mimics Delivered by Stable Nucleic Acid Lipid Particles (SNALPs) against Multiple Myeloma. PLoS ONE, 2014, 9, e90005.	1.1	101
40	Aberrant Glycosylation as Biomarker for Cancer: Focus on CD43. BioMed Research International, 2014, 2014, 1-13.	0.9	100
41	Validation of PDGFRÎ² and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. Blood, 2008, 112, 1346-1356.	0.6	99
42	Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. Nanomedicine: Nanotechnology, Biology, and Medicine, 2011, 7, 955-964.	1.7	98
43	Epigenetic inactivation ofRUNX3 in microsatellite unstable sporadic colon cancers. International Journal of Cancer, 2004, 112, 754-759.	2.3	97
44	miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. Cell Cycle, 2013, 12, 3650-3662.	1.3	96
45	A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells. Clinical Cancer Research, 2016, 22, 1222-1233.	3.2	96
46	Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia, 2008, 22, 1410-1418.	3.3	95
47	Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib*. British Journal of Haematology, 2006, 134, 145-156.	1.2	94
48	Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma. Molecular Cancer Therapeutics, 2016, 15, 1364-1375.	1.9	94
49	Combination Therapy with Interleukin-6 Receptor Superantagonist Sant7 and Dexamethasone Induces Antitumor Effects in a Novel SCID-hu In vivo Model of Human Multiple Myeloma. Clinical Cancer Research, 2005, 11, 4251-4258.	3.2	93
50	A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia, 2011, 25, 707-711.	3.3	93
51	Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity. Oncotarget, 2014, 5, 3039-3054.	0.8	92
52	Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts. Oncotarget, 2015, 6, 27343-27358.	0.8	89
53	Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo. Cancer Biology and Therapy, 2009, 8, 648-653.	1.5	88
54	Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia. Clinical Cancer Research, 2013, 19, 3130-3142.	3.2	86

#	Article	IF	Citations
55	A p53â€Dependent Tumor Suppressor Network Is Induced by Selective miRâ€125aâ€5p Inhibition in Multiple Myeloma Cells. Journal of Cellular Physiology, 2014, 229, 2106-2116.	2.0	86
56	NF-ÎºB/Rel-mediated regulation of apoptosis in hematologic malignancies and normal hematopoietic progenitors. Leukemia, 2004, 18, 11-17.	3.3	84
57	Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma. Current Cancer Drug Targets, 2012, 12, 838-846.	0.8	84
58	Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. Cancer Biology and Therapy, 2013, 14, 469-475.	1.5	82
59	New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-?) treatment of human cancer. Cancer Immunology, Immunotherapy, 2005, 54, 1-10.	2.0	81
60	A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. British Journal of Cancer, 2014, 111, 660-666.	2.9	80
61	Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma. Leukemia, 2020, 34, 234-244.	3.3	80
62	Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: A DMET microarray profiling study. Cancer Biology and Therapy, 2011, 12, 780-787.	1.5	79
63	The Cyclophilin Aâ€“CD147 complex promotes the proliferation and homing of multiple myeloma cells. Nature Medicine, 2015, 21, 572-580.	15.2	79
64	In Vitro and In Vivo Activity of a Novel Locked Nucleic Acid (LNA)-Inhibitor-miR-221 against Multiple Myeloma Cells. PLoS ONE, 2014, 9, e89659.	1.1	77
65	The farnesyl transferase inhibitor R115777 (ZarnestraÂ®) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (ZometaÂ®) and Pamidronate. Oncogene, 2004, 23, 6900-6913.	2.6	73
66	Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia. BMC Medical Genomics, 2013, 6, 27.	0.7	73
67	Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. Leukemia, 2018, 32, 996-1002.	3.3	73
68	Tumor Infiltration by T Lymphocytes Expressing Chemokine Receptor 7 (CCR7) Is Predictive of Favorable Outcome in Patients with Advanced Colorectal Carcinoma. Clinical Cancer Research, 2012, 18, 850-857.	3.2	72
69	Protein Kinase CK2 Protects Multiple Myeloma Cells from ER Stressâ€“Induced Apoptosis and from the Cytotoxic Effect of HSP90 Inhibition through Regulation of the Unfolded Protein Response. Clinical Cancer Research, 2012, 18, 1888-1900.	3.2	71
70	The expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma. Blood Cancer Journal, 2012, 2, e96-e96.	2.8	70
71	Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma. Expert Opinion on Biological Therapy, 2013, 13, S125-S137.	1.4	70
72	A peroxisome proliferatorâ€activated receptor gamma (PPARG) polymorphism is associated with zoledronic acidâ€related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling. British Journal of Haematology, 2011, 154, 529-533.	1.2	69

#	Article	IF	Citations
73	Immunity Feedback and Clinical Outcome in Colon Cancer Patients Undergoing Chemoimmunotherapy with Gemcitabine + FOLFOX followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Aldesleukin (GOLFIG-1 Trial). Clinical Cancer Research, 2008, 14, 4192-4199.	3.2	68
74	DMETâ„¢ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine. Oncotarget, 2016, 7, 54028-54050.	0.8	68
75	EGF activates an inducible survival response via the RAS-> Erk-1/2 pathway to counteract interferon-Î±-mediated apoptosis in epidermoid cancer cells. Cell Death and Differentiation, 2003, 10, 218-229.	5.0	67
76	DMET-Analyzer: automatic analysis of Affymetrix DMET Data. BMC Bioinformatics, 2012, 13, 258.	1.2	66
77	The Eukaryotic Initiation Factor 5A Is Involved in the Regulation of Proliferation and Apoptosis Induced by Interferon-Â and EGF in Human Cancer Cells. Journal of Biochemistry, 2003, 133, 757-765.	0.9	65
78	Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease. Scientific Reports, 2020, 10, 2565.	1.6	63
79	In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2009, 64, 1009-1020.	1.1	62
80	Nanoparticle Albumin Bound Paclitaxel in the Treatment of Human Cancer: Nanodelivery Reaches Prime-Time?. Journal of Drug Delivery, 2013, 2013, 1-10.	2.5	62
81	Establishment of BCWM.1 cell line for WaldenstrÃ¶m's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. Experimental Hematology, 2007, 35, 1366-1375.	0.2	61
82	Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features. Clinical Cancer Research, 2013, 19, 5890-5900.	3.2	60
83	Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma. Molecular Cancer Therapeutics, 2016, 15, 1364-1375.	1.9	60
84	The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment. Leukemia, 2017, 31, 1570-1581.	3.3	60
85	Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma. Oncotarget, 2017, 8, 106527-106537.	0.8	60
86	Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. Blood, 2005, 105, 4470-4476.	0.6	59
87	In vivo antiâ€myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. British Journal of Haematology, 2008, 143, 520-531.	1.2	59
88	Molecular Targets for the Treatment of Multiple Myeloma. Current Cancer Drug Targets, 2012, 12, 757-767.	0.8	59
89	Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC). European Journal of Cancer, 2010, 46, 1703-1711.	1.3	58
90	Epstein-Barr virus nuclear antigen 2 transactivates the long terminal repeat of human immunodeficiency virus type 1. Journal of Virology, 1993, 67, 2853-2861.	1.5	58

#	Article	IF	Citations
91	Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cellsin vitroandin vivo. Molecular Cancer Therapeutics, 2009, 8, 26-35.	1.9	57
92	Myeloid-Derived Suppressor Cells in Multiple Myeloma: Pre-Clinical Research and Translational Opportunities. Frontiers in Oncology, 2014, 4, 348.	1.3	57
93	Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trials. Oncology Reports, 2012, 27, 1849-56.	1.2	55
94	SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood, 2005, 106, 706-712.	0.6	54
95	Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation. Expert Opinion on Therapeutic Targets, 2017, 21, 91-101.	1.5	54
96	Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients. Blood Advances, 2017, 1, 455-466.	2.5	54
97	p38 mitogenâ€activated protein kinase inhibitor LY2228820 enhances bortezomibâ€induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. British Journal of Haematology, 2008, 141, 598-606.	1.2	53
98	microRNAome Expression in Chronic Lymphocytic Leukemia: Comparison with Normal B-cell Subsets and Correlations with Prognostic and Clinical Parameters. Clinical Cancer Research, 2014, 20, 4141-4153.	3.2	52
99	Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse. Cancer Biology and Therapy, 2016, 17, 1213-1220.	1.5	52
100	Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92. Blood, 2018, 132, 1050-1063.	0.6	52
101	MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells. Leukemia, 2018, 32, 1003-1015.	3.3	51
102	Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives. Critical Reviews in Oncology/Hematology, 2019, 140, 67-72.	2.0	51
103	Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome. Clinical Cancer Research, 2013, 19, 3247-3258.	3.2	50
104	miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth. Blood Cancer Journal, 2016, 6, e380-e380.	2.8	50
105	MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment. BioMed Research International, 2016, 2016, 1-12.	0.9	49
106	miR-221 stimulates breast cancer cells and cancer-associated fibroblasts (CAFs) through selective interference with the A20/c-Rel/CTGF signaling. Journal of Experimental and Clinical Cancer Research, 2018, 37, 94.	3.5	49
107	Significant Biological Role of Sp1 Transactivation in Multiple Myeloma. Clinical Cancer Research, 2011, 17, 6500-6509.	3.2	47
108	lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome. Blood Cancer Journal, 2016, 6, e468-e468.	2.8	47

#	Article	IF	Citations
109	Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma. Cancers, 2019, 11, 990.	1.7	47
110	miRNAs and lncRNAs as Novel Therapeutic Targets to Improve Cancer Immunotherapy. Cancers, 2021, 13, 1587.	1.7	47
111	Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates. Molecular Therapy - Nucleic Acids, 2016, 5, e326.	2.3	46
112	MicroRNA and Multiple Myeloma: from Laboratory Findings to Translational Therapeutic Approaches. Current Pharmaceutical Biotechnology, 2014, 15, 459-467.	0.9	46
113	Radiomics predicts survival of patients with advanced nonâ€‘small cell lung cancer undergoing PDâ€‘1 blockade using Nivolumab. Oncology Letters, 2020, 19, 1559-1566.	0.8	46
114	Mouse Models as a Translational Platform for the Development of New Therapeutic Agents in Multiple Myeloma. Current Cancer Drug Targets, 2012, 12, 814-822.	0.8	45
115	Transferrin-Conjugated SNALPs Encapsulating 2â€²-O-Methylated miR-34a for the Treatment of Multiple Myeloma. BioMed Research International, 2014, 2014, 1-7.	0.9	45
116	Pegylated liposomal doxorubicin in the management of ovarian cancer. Cancer Biology and Therapy, 2014, 15, 707-720.	1.5	45
117	Mir-221/222 are promising targets for innovative anticancer therapy. Expert Opinion on Therapeutic Targets, 2016, 20, 1099-1108.	1.5	45
118	From Target Therapy to miRNA Therapeutics of Human Multiple Myeloma: Theoretical and Technological Issues in the Evolving Scenario. Current Drug Targets, 2013, 14, 1144-1149.	1.0	45
119	MicroRNAs in the Pathobiology of Multiple Myeloma. Current Cancer Drug Targets, 2012, 12, 823-837.	0.8	44
120	Enhancement of cytosine arabinoside-induced apoptosis in human myeloblastic leukemia cells by NF-ÎºB/Relâ˜ specific decoy oligodeoxynucleotides. Gene Therapy, 2000, 7, 1234-1237.	2.3	42
121	Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis. Cancer Chemotherapy and Pharmacology, 2016, 77, 205-209.	1.1	42
122	Pharmacogenomics Biomarker Discovery and Validation for Translation in Clinical Practice. Clinical and Translational Science, 2021, 14, 113-119.	1.5	42
123	Physicochemical features and transfection properties of chitosan/poloxamer 188/poly(D,L-lactide-co-glycolide) nanoplexes. International Journal of Nanomedicine, 2014, 9, 2359.	3.3	41
124	Gemcitabine, Oxaliplatin, Levofolinate, 5-Fluorouracil, Granulocyte-Macrophage Colony-Stimulating Factor, and Interleukin-2 (GOLFIG) Versus FOLFOX Chemotherapy in Metastatic Colorectal Cancer Patients. Journal of Immunotherapy, 2014, 37, 26-35.	1.2	41
125	A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?. Cancer Biology and Therapy, 2015, 16, 1148-1159.	1.5	41
126	Disentangling the microRNA regulatory‹i›milieu‹/i›in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients. Oncotarget, 2016, 7, 2367-2378.	0.8	41

#	Article	IF	Citations
127	Early blood rise in autoâ€'antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastaticâ€'nonâ€'small cell lung cancer patients treated with PDâ€'1 immuneâ€'check point blockade by nivolumab. Molecular and Clinical Oncology, 2019, 11, 81-90.	0.4	41
128	Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma. Oncotarget, 2015, 6, 19132-19147.	0.8	41
129	Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro. Cancer Biology and Therapy, 2014, 15, 797-805.	1.5	40
130	Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment. Oncotarget, 2017, 8, 100831-100851.	0.8	40
131	A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias. Oncotarget, 2015, 6, 26129-26141.	0.8	40
132	miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review. Molecular Therapy - Nucleic Acids, 2022, 27, 1191-1224.	2.3	40
133	Immunologic microenvironment and personalized treatment in multiple myeloma. Expert Opinion on Biological Therapy, 2013, 13, S83-S93.	1.4	39
134	miR-22 suppresses DNA ligase III addiction in multiple myeloma. Leukemia, 2019, 33, 487-498.	3.3	39
135	Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance. Blood, 2009, 114, 3276-3284.	0.6	38
136	A SCID-hu in vivo model of human Waldenstroì¨m macroglobulinemia. Blood, 2005, 106, 1341-1345.	0.6	37
137	The oral protein-kinase CÎ²inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. Leukemia and Lymphoma, 2008, 49, 1374-1383.	0.6	37
138	Emerging pathways as individualized therapeutic target of multiple myeloma. Expert Opinion on Biological Therapy, 2013, 13, S95-S109.	1.4	37
139	A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival. Blood Cancer Journal, 2016, 6, e511-e511.	2.8	37
140	The Era of PARP inhibitors in ovarian cancer: â€œClass Actionâ€•or not? A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2018, 131, 83-89.	2.0	37
141	HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis. Cells, 2020, 9, 1964.	1.8	37
142	Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment. Scientific Reports, 2017, 7, 17949.	1.6	36
143	Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients. Journal of Ovarian Research, 2016, 9, 31.	1.3	35
144	Mouse models of multiple myeloma: technologic platforms and perspectives. Oncotarget, 2018, 9, 20119-20133.	0.8	35

#	Article	IF	Citations
145	Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. Cancers, 2019, 11, 236.	1.7	35
146	Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab in advanced non-small-cell-lung cancer patients. Cancer Biology and Therapy, 2010, 9, 685-693.	1.5	34
147	Immune-modulating Effects of the Newest Cetuximab-based Chemoimmunotherapy Regimen in Advanced Colorectal Cancer Patients. Journal of Immunotherapy, 2012, 35, 440-447.	1.2	34
148	Cutting the Limits of Aminobisphosphonates: New Strategies for the Potentiation of their Anti-Tumour Effects. Current Cancer Drug Targets, 2009, 9, 791-800.	0.8	33
149	Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy. Leukemia, 2017, 31, 1894-1904.	3.3	33
150	Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma. Haematologica, 2020, 106, 185-195.	1.7	33
151	miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma. Leukemia, 2021, 35, 823-834.	3.3	33
152	Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade. , 2020, 8, e000733.		32
153	Synergistic induction of growth arrest and apoptosis of human myeloma cells by the IL-6 super-antagonist Sant7 and Dexamethasone. Cell Death and Differentiation, 2000, 7, 327-328.	5.0	31
154	Proteasomal Degradation of Topoisomerase I Is Preceded by c-Jun NH2-Terminal Kinase Activation, Fas Up-Regulation, and Poly(ADP-Ribose) Polymerase Cleavage in SN38-Mediated Cytotoxicity against Multiple Myeloma. Cancer Research, 2004, 64, 8746-8753.	0.4	30
155	Multiple myeloma: Monoclonal antibodies-based immunotherapeutic strategies and targeted radiotherapy. European Journal of Cancer, 2006, 42, 1640-1652.	1.3	30
156	miR-125b Upregulates miR-34a and Sequentially Activates Stress Adaption and Cell Death Mechanisms in Multiple Myeloma. Molecular Therapy - Nucleic Acids, 2019, 16, 391-406.	2.3	30
157	Genetics and molecular profiling of multiple myeloma: Novel tools for clinical management?. European Journal of Cancer, 2006, 42, 1530-1538.	1.3	29
158	Tumor infiltration by chemokine receptor 7 (CCR7)⁺T-lymphocytes is a favorable prognostic factor in metastatic colorectal cancer. OncoImmunology, 2012, 1, 531-532.	2.1	29
159	Alternative Non-Homologous End-Joining: Error-Prone DNA Repair as Cancerâ€™s Achillesâ€™ Heel. Cancers, 2021, 13, 1392.	1.7	29
160	Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. Journal of Hematology and Oncology, 2019, 12, 32.	6.9	28
161	Polymorphic Variants in <scp>NR</scp>1I3 and <scp>UGT</scp>2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Caseâ€Control Study. Clinical Pharmacology and Therapeutics, 2019, 106, 422-431.	2.3	27
162	Long non-coding RNA NEAT1 shows high expression unrelated to molecular features and clinical outcome in multiple myeloma. Haematologica, 2019, 104, e72-e76.	1.7	27

#	Article	IF	Citations
163	LncRNA NEAT1 in Paraspeckles: A Structural Scaffold for Cellular DNA Damage Response Systems?. Non-coding RNA, 2020, 6, 26.	1.3	27
164	Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. ESMO Open, 2022, 7, 100459.	2.0	26
165	Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma. Leukemia, 2007, 21, 2519-2526.	3.3	24
166	Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients. OncoImmunology, 2016, 5, e1101205.	2.1	24
167	The Non-Coding RNA Landscape of Plasma Cell Dyscrasias. Cancers, 2020, 12, 320.	1.7	24
168	Mass Spectrometry-Based Identification Of The Tumor Antigen UN1 as the Transmembrane CD43 Sialoglycoprotein. Molecular and Cellular Proteomics, 2011, 10, M111.007898.	2.5	23
169	Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2015, 56, 3150-3158.	0.6	23
170	The potential role of miRNAs in multiple myeloma therapy. Expert Review of Hematology, 2018, 11, 793-803.	1.0	23
171	A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. European Journal of Medicinal Chemistry, 2019, 183, 111715.	2.6	23
172	An Anti-BCMA RNA Aptamer for miRNA Intracellular Delivery. Molecular Therapy - Nucleic Acids, 2019, 18, 981-990.	2.3	23
173	Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev). Oncotarget, 2017, 8, 75904-75913.	0.8	23
174	Detection of microsatellite instability and loss of heterozygosity in serum DNA of small and non-small cell lung cancer patients: a tool for early diagnosis?. Lung Cancer, 2000, 30, 211-214.	0.9	22
175	BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality?. Journal of Ovarian Research, 2009, 2, 14.	1.3	22
176	Analysis of miRNA, mRNA, and TF interactions through network-based methods. Eurasip Journal on Bioinformatics and Systems Biology, 2015, 2015, 4.	1.4	22
177	Evidence of shared epitopic reactivity among independent B-cell clones in chronic lymphocytic leukemia patients. Leukemia, 2016, 30, 2419-2422.	3.3	22
178	Transcriptional regulation of the mismatch repair gene hMLH1. Gene, 2001, 275, 261-265.	1.0	21
179	The farnesyltransferase inhibitor R115777 (ZARNESTRAÂ®) enhances the proâ€apoptotic activity of interferonâ€Î± through the inhibition of multiple survival pathways. International Journal of Cancer, 2007, 121, 2317-2330.	2.3	21
180	Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients. Cancer Immunology, Immunotherapy, 2015, 64, 1159-1173.	2.0	21

#	Article	IF	Citations
181	Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients. Future Oncology, 2016, 12, 2071-2075.	1.1	21
182	Development and validation of a bioanalytical method for quantification of LNA-i-miR-221, a 13-mer oligonucleotide, in rat plasma using LCâ€“MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2018, 150, 300-307.	1.4	21
183	Challenging the Current Approaches to Multiple Myeloma-Related Bone Disease: From Bisphosphonates to Target Therapy. Current Cancer Drug Targets, 2009, 9, 854-870.	0.8	20
184	Molecular profiling of multiple myeloma: from gene expression analysis to next-generation sequencing. Expert Opinion on Biological Therapy, 2013, 13, S55-S68.	1.4	20
185	The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells. International Journal of Oncology, 2002, 21, 867-73.	1.4	20
186	Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine. Cancer Biology and Therapy, 2009, 8, 497-502.	1.5	19
187	Immunotherapy of colorectal cancer: new perspectives after a long path. Immunotherapy, 2016, 8, 1281-1292.	1.0	19
188	FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology. Blood Advances, 2022, 6, 690-703.	2.5	19
189	MicroRNAs in multiple myeloma and related bone disease. Annals of Translational Medicine, 2015, 3, 334.	0.7	19
190	In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells. British Journal of Haematology, 2006, 134, 37-44.	1.2	18
191	The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response. Cell Death and Disease, 2016, 7, e2299-e2299.	2.7	18
192	Anti-cancer activity of dose-fractioned mPE +/âˆ’ bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients. Journal of Thoracic Disease, 2017, 9, 3123-3131.	0.6	18
193	Novel Therapeutic Approaches Based on the Targeting of Microenvironment-Derived Survival Pathways in Human Cancer: Experimental Models and Translational Issues. Current Pharmaceutical Design, 2007, 13, 487-496.	0.9	17
194	Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model. Experimental Hematology, 2007, 35, 1038-1046.	0.2	17
195	Automatic summarisation and annotation of microarray data. Soft Computing, 2011, 15, 1505-1512.	2.1	17
196	Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer. Pancreatology, 2016, 16, 249-258.	0.5	17
197	Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit) Tj ETQq1 1 0.784314 rgBT /Overlock	1.3	
198	The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis. Critical Reviews in Oncology/Hematology, 2018, 125, 69-77.	2.0	17

#	Article	IF	Citations
199	Synthesis and preliminary evaluation of the anti-cancer activity on A549 lung cancer cells of a series of unsaturated disulfides. MedChemComm, 2019, 10, 116-119.	3.5	17
200	Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents. International Journal of Oncology, 2005, 26, 1257-63.	1.4	17
201	MYD88-independent growth and survival effects of Sp1 transactivation in WaldenstrÃ¶m macroglobulinemia. Blood, 2014, 123, 2673-2681.	0.6	16
202	Functional Analysis of microRNA in Multiple Myeloma. Methods in Molecular Biology, 2015, 1375, 181-194.	0.4	16
203	Non Coding RNAs: A New Avenue for the Self-Tailoring of Blood Cancer Treatment. Current Drug Targets, 2016, 18, 35-55.	1.0	16
204	The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells. International Journal of Oncology, 2002, 21, 867.	1.4	15
205	Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine. Oncotarget, 2018, 9, 20539-20554.	0.8	15
206	GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up. Frontiers in Oncology, 2019, 9, 1102.	1.3	15
207	Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report. Frontiers in Oncology, 2020, 10, 579445.	1.3	15
208	Antitumor Therapeutic Strategies Based on the Targeting of Epidermal Growth Factor-Induced Survival Pathways. Current Drug Targets, 2005, 6, 289-300.	1.0	15
209	OSAnalyzer: A Bioinformatics Tool for the Analysis of Gene Polymorphisms Enriched with Clinical Outcomes. Microarrays (Basel, Switzerland), 2016, 5, 24.	1.4	14
210	mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials. Oncotarget, 2016, 7, 27055-27066.	0.8	14
211	Impact of Natural Dietary Agents on Multiple Myeloma Prevention and Treatment: Molecular Insights and Potential for Clinical Translation. Current Medicinal Chemistry, 2020, 27, 187-215.	1.2	14
212	UN1, a murine monoclonal antibody recognizing a novel human thymic antigen. Tissue Antigens, 1994, 44, 73-82.	1.0	13
213	Allometric Scaling Approaches for Predicting Human Pharmacokinetic of a Locked Nucleic Acid Oligonucleotide Targeting Cancer-Associated miR-221. Cancers, 2020, 12, 27.	1.7	13
214	Errorâ€prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment. International Journal of Cancer, 2020, 147, 2658-2668.	2.3	13
215	miR-22 Modulates Lenalidomide Activity by Counteracting MYC Addiction in Multiple Myeloma. Cancers, 2021, 13, 4365.	1.7	13
216	Identification by Differential Display of Transcripts Regulated during Hematopoietic Differentiation. Stem Cells, 1998, 16, 136-143.	1.4	12

#	Article	IF	Citations
217	Immunomodulatory activity of microRNAs: potential implications for multiple myeloma treatment. Current Cancer Drug Targets, 2017, 17, 1-1.	0.8	12
218	Oxaliplatin (L-OHP) treatment of human myeloma cells induces in vitro growth inhibition and apoptotic cell death. European Journal of Cancer, 2002, 38, 1141-1147.	1.3	11
219	Human mismatch-repair protein MutL homologue 1 (MLH1) interacts with Escherichia coli MutL and MutS in vivo and in vitro: a simple genetic system to assay MLH1 function. Biochemical Journal, 2003, 371, 183-189.	1.7	11
220	Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents. International Journal of Oncology, 2005, 26, 1257.	1.4	11
221	DMETTM Genotyping: Tools for Biomarkers Discovery in the Era of Precision Medicine. High-Throughput, 2020, 9, 8.	4.4	11
222	Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia. , 2021, 9, e002026.		11
223	A Phase I, Multi-Center, Dose Escalation Study of Atiprimod in Patients with Refractory or Relapsed Multiple Myeloma (MM).. Blood, 2005, 106, 111-111.	0.6	10
224	Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation. Oncotarget, 2016, 7, 82741-82756.	0.8	10
225	Hereditary nonpolyposis colorectal cancer: Identification of novel germline mutations in two kindreds not fulfilling the Amsterdam criteria. , 1998, 12, 433-433.		9
226	Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats. Molecular Therapy - Nucleic Acids, 2020, 20, 73-85.	2.3	9
227	A Novel Bispecific T-Cell Engager (CD1a x CD3Îµ) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells. Cancers, 2022, 14, 2886.	1.7	9
228	Purification and characterization of a human sialoglycoprotein antigen expressed in immature thymocytes and fetal tissues. Tissue Antigens, 1998, 51, 528-535.	1.0	8
229	Triggering of CD40 Antigen Inhibits Fludarabine-Induced Apoptosis in B Chronic Lymphocytic Leukemia Cells. Blood, 1998, 92, 990-995.	0.6	8
230	Targeting PI3K and RAD51 in Barrett's adenocarcinoma: impact on DNA damage checkpoints, expression profile and tumor growth. Cancer Genomics and Proteomics, 2012, 9, 55-66.	1.0	8
231	Regulation of NF-Î²B Nuclear Activity in Peripheral Blood Mononuclear Cells: Role of CD28 Antigen. Cellular Immunology, 1994, 156, 371-377.	1.4	7
232	CD69 expression on primitive progenitor cells and hematopoietic malignancies. Tissue Antigens, 1996, 48, 65-68.	1.0	7
233	Partial purification and MALDI-TOF MS analysis of UN1, a tumor antigen membrane glycoprotein. International Journal of Biological Macromolecules, 2006, 39, 122-126.	3.6	7
234	A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?. Journal of Ovarian Research, 2013, 6, 10.	1.3	7

#	Article	IF	Citations
235	Influence of the Fabrication Accuracy of Hot-Embossed PCL Scaffolds on Cell Growths. Frontiers in Bioengineering and Biotechnology, 2020, 8, 84.	2.0	7
236	Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis. Life, 2021, 11, 1235.	1.1	7
237	Chromene Derivatives as Selective TERRA G-Quadruplex RNA Binders with Antiproliferative Properties. Pharmaceuticals, 2022, 15, 548.	1.7	7
238	Ink Spot Lentigo: Singular Clinical Features in a Case Series of Patients. International Journal of Immunopathology and Pharmacology, 2013, 26, 953-955.	1.0	6
239	Alternative non-homologous end joining repair: a master regulator of genomic instability in cancer. Precision Cancer Medicine, 0, 2, 8-8.	1.8	6
240	Expression Pattern and Biological Significance of the lncRNA ST3GAL6-AS1 in Multiple Myeloma. Cancers, 2020, 12, 782.	1.7	6
241	Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data. Journal of Computational Science, 2021, 51, 101346.	1.5	6
242	Differential expression of UN1, early thymocyte-associated sialoglycoprotein, in breast normal tissue, benign disease and carcinomas. Anticancer Research, 2002, 22, 2333-40.	0.5	6
243	Defect of Interleukin-2 Production and T Cell Proliferation in Atopic Patients: Restoring Ability of the CD28-Mediated Activation Pathway. Cellular Immunology, 1993, 148, 455-463.	1.4	5
244	Pegylated liposomal doxorubicin is active in Stewartâ€“Treves syndrome. Annals of Oncology, 2007, 18, 959-960.	0.6	5
245	Enumeration of interleukin-10-positive B cells from peripheral blood of patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2014, 55, 1394-1396.	0.6	5
246	Experimental treatment of multiple myeloma in the era of precision medicine. Expert Review of Precision Medicine and Drug Development, 2016, 1, 37-51.	0.4	5
247	Development and validation of bioanalytical methods for LNA-i-miR-221 quantification in human plasma and urine by LC-MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2020, 188, 113451.	1.4	5
248	In Vitro Silencing of lncRNAs Using LNA GapmeRs. Methods in Molecular Biology, 2021, 2348, 157-166.	0.4	5
249	Establishment of a Waldenstromâ€™s Macroglobulinemia Cell Line (BCWM.1) with Productive In Vivo Engraftment in SCID-hu Mice.. Blood, 2005, 106, 979-979.	0.6	5
250	CD36 is rapidly and transiently upregulated on phytohemagglutinin (PHA)â€stimulated peripheral blood lymphocytes. Analysis by a new monoclonal antibody (UN7). Tissue Antigens, 1998, 51, 671-675.	1.0	4
251	MMRF-CoMMpass Data Integration and Analysis for Identifying Prognostic Markers. Lecture Notes in Computer Science, 2020, , 564-571.	1.0	4
252	Oleil Hydroxytyrosol (HTOL) Exerts Anti-Myeloma Activity by Antagonizing Key Survival Pathways in Malignant Plasma Cells. International Journal of Molecular Sciences, 2021, 22, 11639.	1.8	4

#	Article	IF	Citations
253	Risk Alleles for Multiple Myeloma Susceptibility in ADME Genes. Cells, 2022, 11, 189.	1.8	4
254	Fetal ontogeny and tumor expression of the early thymic antigen UN1. International Journal of Oncology, 2002, 20, 707-11.	1.4	4
255	BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories. Diagnostics, 2019, 9, 146.	1.3	3
256	Aberrant Non-Homologous End Joining in Multiple Myeloma: A Role in Genomic Instability and As Potential Prognostic Marker.. Blood, 2012, 120, 2932-2932.	0.6	3
257	Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232110630.	1.1	3
258	Integration of DNA Microarray with Clinical and Genomic Data. Methods in Molecular Biology, 2022, 2401, 239-248.	0.4	3
259	A novel monoclonal antibody recognizing human thymocytes and B-cell chronic lymphocytic leukemia cells. Immunology Letters, 1994, 39, 137-146.	1.1	2
260	The IASLC Lung Cancer Staging Project: Revision Proposal of Pleural Effusion and Controlateral Nodule Staging. Journal of Thoracic Oncology, 2008, 3, 317.	0.5	2
261	Amifostine Inhibits Hematopoietic Progenitor Cell Apoptosis by Activating NF-Î°B/Rel Transcription Factors. Blood, 1999, 94, 4060-4066.	0.6	2
262	On the way of the new strategies aimed to improve the efficacy of PD-1/PD-L1 immune checkpoint blocking mAbs in small cell lung cancer. Translational Lung Cancer Research, 2020, 9, 1712-1719.	1.3	2
263	Analysis of peripheral blood normal and malignant cells with the novel murine monoclonal antibody UN2. Immunology Letters, 1994, 42, 55-62.	1.1	1
264	Challenges in Multiple Myeloma Chemoprevention: Potential Role of Natural, Synthetic and Endogenous Molecules. , 2016, , 37-60.		1
265	Pharmacogenetics/Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters. , 2021, , .		1
266	An Extension of the TIGR M4 Suite to Preprocess and Visualize Affymetrix Binary Files. Lecture Notes in Computer Science, 2009, , 265-274.	1.0	1
267	Novel Hydroxamic Acid-Derived HDAC Inhibitor LBH589 Potently Activates Intrinsic and Extrinsic Apoptotic Pathways, and Induces Tubulin Hyperacetylation in Multiple Myeloma.. Blood, 2005, 106, 1578-1578.	0.6	1
268	A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics. Biomedicines, 2022, 10, 1210.	1.4	1
269	Detection of an antigenic marker expressed by peripheral blood monocytes and platelets by a new monoclonal antibody UN8. Tissue Antigens, 1995, 45, 288-291.	1.0	0
270	Molecular Rationales for Signal Transduction Therapy and Chemoprevention of BRCA1-Related Breast and Ovarian Tumours. Current Signal Transduction Therapy, 2007, 2, 165-173.	0.3	0

#	Article	IF	Citations
271	Monoclonal Antibodyâ€“Based Therapies in Human Multiple Myeloma. Clinical Lymphoma and Myeloma, 2009, 9, S22-S23.	1.4	0
272	Pharmacological Approaches for BRCA1/2 Related Breast and Ovarian Cancer: Preclinical Studies and Early Clinical Trials. Current Women's Health Reviews, 2012, 8, 104-110.	0.1	0
273	DMET-miner: Efficient learning of association rules from genotyping data for personalized medicine. , 2014, , .		0
274	Multiple myeloma-related bone disease: state-of-art and next future treatments. International Journal of Hematologic Oncology, 2015, 4, 33-47.	0.7	0
275	Precision Oncology: Present Status and Perspectives. Current Clinical Pathology, 2017, , 7-26.	0.0	0
276	A Clinically Relevant SCID-hu in Vivo Model of Human Multiple Myeloma.. Blood, 2004, 104, 2455-2455.	0.6	0
277	Atiprimod (N-N-diethl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) Inhibits Myeloma in Vivo.. Blood, 2004, 104, 2401-2401.	0.6	0
278	Inhibition of Human Plasmacytoma Cell Growth by a Novel JAK Kinase Inhibitor.. Blood, 2004, 104, 644-644.	0.6	0
279	Targeting Mitochondrial Factor Smac/DIABLO as Therapy for Multiple Myeloma (MM).. Blood, 2004, 104, 764-764.	0.6	0
280	Elevated Apurinic/Apyrimidinic Endonuclease Activity Significantly Contributes to DNA Instability in Multiple Myeloma.. Blood, 2006, 108, 2077-2077.	0.6	0
281	Modulation of Gene Expression Profile and In Vivo Anti-Myeloma Activity Induced by Valproic Acid, a Histone Deacytylase Inhibitor.. Blood, 2007, 110, 4790-4790.	0.6	0
282	SCID-Synth-Hu: a Novel Multiple Myeloma Model for In Vivo Expansion of Primary Cells. Blood, 2010, 116, 452-452.	0.6	0
283	The Expression Pattern of Small Nucleolar and Small Cajal Body-Specific RNAs Characterizes Distinct Molecular Subtypes of Multiple Myeloma. Blood, 2012, 120, 3955-3955.	0.6	0
284	MiR-29b Counteracts Aberrant HDAC4 Expression and Enhances Vorinostat Activity in Multiple Myeloma. Blood, 2014, 124, 2060-2060.	0.6	0
285	On the way of the new strategies aimed to improve the efficacy of PD-1/PD-L1 immune checkpoint blocking mAbs in small cell lung cancer. Translational Lung Cancer Research, 2020, 9, 1712-1719.	1.3	0
286	Identification of SET/EED dual binders as innovative PRC2 inhibitors. Future Medicinal Chemistry, 2022, , .	1.1	0